Te Ahumairangi Investment Management Ltd trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 6.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,413 shares of the pharmaceutical company's stock after selling 926 shares during the period. Te Ahumairangi Investment Management Ltd's holdings in Vertex Pharmaceuticals were worth $4,999,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently added to or reduced their stakes in VRTX. Captrust Financial Advisors boosted its stake in shares of Vertex Pharmaceuticals by 2.2% during the 3rd quarter. Captrust Financial Advisors now owns 14,409 shares of the pharmaceutical company's stock valued at $6,701,000 after buying an additional 307 shares during the last quarter. Benjamin Edwards Inc. raised its stake in shares of Vertex Pharmaceuticals by 4,913.5% in the 3rd quarter. Benjamin Edwards Inc. now owns 6,668 shares of the pharmaceutical company's stock valued at $3,101,000 after purchasing an additional 6,535 shares in the last quarter. Hilltop Holdings Inc. lifted its position in shares of Vertex Pharmaceuticals by 359.5% during the third quarter. Hilltop Holdings Inc. now owns 3,143 shares of the pharmaceutical company's stock worth $1,462,000 after purchasing an additional 2,459 shares during the last quarter. HighTower Advisors LLC grew its stake in Vertex Pharmaceuticals by 7.6% in the third quarter. HighTower Advisors LLC now owns 57,242 shares of the pharmaceutical company's stock worth $26,494,000 after purchasing an additional 4,048 shares in the last quarter. Finally, Harmony Asset Management LLC increased its holdings in Vertex Pharmaceuticals by 12.7% in the third quarter. Harmony Asset Management LLC now owns 6,917 shares of the pharmaceutical company's stock valued at $3,217,000 after buying an additional 777 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company's stock.
Insider Activity at Vertex Pharmaceuticals
In other news, EVP Ourania Tatsis sold 310 shares of the business's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $459.83, for a total transaction of $142,547.30. Following the sale, the executive vice president now directly owns 64,021 shares in the company, valued at approximately $29,438,776.43. The trade was a 0.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP David Altshuler sold 3,231 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $500.00, for a total value of $1,615,500.00. Following the completion of the transaction, the executive vice president now directly owns 26,512 shares of the company's stock, valued at approximately $13,256,000. This trade represents a 10.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 4,315 shares of company stock worth $2,121,012 over the last three months. Company insiders own 0.20% of the company's stock.
Vertex Pharmaceuticals Stock Performance
VRTX traded up $0.52 during midday trading on Thursday, reaching $484.01. The company's stock had a trading volume of 2,063,769 shares, compared to its average volume of 1,286,638. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88. The company has a fifty day simple moving average of $480.84 and a 200 day simple moving average of $463.95. The stock has a market cap of $124.29 billion, a P/E ratio of -220.00, a PEG ratio of 2.11 and a beta of 0.41. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01.
Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. Research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on VRTX. Stifel Nicolaus lifted their target price on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a "hold" rating in a research report on Monday, December 16th. Oppenheimer downgraded shares of Vertex Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Thursday, December 19th. Bank of America lifted their price target on Vertex Pharmaceuticals from $555.00 to $567.00 and gave the company a "buy" rating in a research report on Monday. Scotiabank boosted their target price on shares of Vertex Pharmaceuticals from $433.00 to $450.00 and gave the stock a "sector perform" rating in a report on Tuesday, February 11th. Finally, Truist Financial increased their price target on Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a "buy" rating in a research report on Tuesday, February 11th. Ten investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $509.17.
Read Our Latest Research Report on Vertex Pharmaceuticals
About Vertex Pharmaceuticals
(
Free Report)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Featured Articles
Before you consider Vertex Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.
While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
